Indications

Chronic Obstructive Pulmonary Disease (COPD) (see Chronic Obstructive Pulmonary Disease)

General Comments

• FDA Approved for This Indication

Clinical Efficacy

• ENHANCE-1 and ENHANCE-2 Trials (Am J Resp Crit Care Med, 2023) [MEDLINE]
  • XXXXX
• xxxx

---

Pharmacology

Dual Phosphodiesterase-3 (PDE3) and Phosphodiesterase-4 (PDE4) Inhibitor

• Bronchodilator Effects
• Anti-Inflammatory Effects

Metabolism

XXXX

• xxx

---

Administration

Oral (PO)

• Dose: XXXX

Dose Adjustment

• Hepatic: xxx
• Renal: xxx

Use in Pregnancy (see Pregnancy)

• xxx

Use During Breast Feeding

• xxx

---

Adverse Effects

Pulmonary Adverse Effects

Paradoxical Bronchospasm (see Obstructive Lung Disease)

• Epidemiology
  • XXXXXX
• Clinical
  • XXXXX

Other Adverse Effects

• xxx
• xxx
• xxx
• xxx

---

References

General

• xxx

Adverse Effects

• XXXXX